Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

B Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound.…
posteditor
posteditor
Articles: 17424

Other News